We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.03% | 77.02 | 77.02 | 77.27 | 77.525 | 76.87 | 76.94 | 3,870,939 | 23:31:43 |
From May 2022 to May 2024
By Kyle Morris
AstraZeneca PLC said Monday that Enhertu has been recommended for approval in the European Union for patients with gastric cancer.
The Anglo-Swedish pharma major said Enhertu--trastuzumab deruxtecan--has been recommended in the EU by the European Medicines Agency as monotherapy for the treatment of patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
Enhertu is a specifically engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
November 14, 2022 02:37 ET (07:37 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
